MorphoSys AG (MOR) will know whether or not its drug candidate Tafasitamab in combination with Revlimid, proposed for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma, gets FDA approval on August 30, 2020.Tafasitamab is a humanized Fc-engineered monoclonal antibody directed against the protein CD19, expressed across different B cell-derived blood cancers including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). MorphoSys licensed exclusive worldwide rights to develop and commercialize Tafasitamab from Xencor, Inc (XNCR) in 2010. Early this year, MorphoSys and Incyte (INCY) inked a deal to co-commercialize Tafasitamab in the U.S.Outside of the U.S., Incyte has exclusive commercialization rights to Tafasitamab.Tafasitamab is also under review by the European Medicines Agency.MOR closed Friday’s (Jul.24, 2020) trading at $32.74, down 4.02%.